respiratori
virus
rv
increasingli
recogn
major
caus
morbid
mortal
solid
organ
transplant
recipi
especi
within
lung
transplant
popul
respiratori
viral
infect
typic
caus
rhinoviru
rhv
coronaviru
cov
respiratori
syncyti
viru
rsv
influenza
flu
parainfluenza
piv
human
metapneumoviru
hmpv
adenoviru
adv
tabl
respiratori
infect
also
caus
virus
less
commonli
associ
respiratori
tract
cytomegaloviru
cmv
human
herpesvirus
varicella
zoster
viru
vzv
discuss
anoth
chapter
chap
detail
discuss
newer
respiratori
virus
tabl
beyond
scope
chapter
sinc
wide
studi
immunocompromis
patient
clinic
impact
fulli
understood
howev
virus
consid
differenti
diagnosi
patient
present
sever
lower
tract
diseas
especi
clinic
histori
indic
potenti
exposur
newer
rv
challeng
diagnos
sinc
includ
routin
avail
diagnost
test
optim
manag
defin
definit
rv
diseas
includ
new
onset
symptom
least
one
respiratori
symptom
clinician
judgment
ill
due
infect
upper
respiratori
tract
infect
urti
defin
onset
sore
throat
rhinorrhea
hoars
lower
respiratori
tract
infect
lrti
defin
new
onset
short
breath
cough
sputum
rale
hypoxemia
andor
wheez
symptom
lrti
associ
new
pulmonari
infiltr
chest
radiograph
chest
comput
tomographi
pneumonia
distinguish
tracheobronch
mani
common
respiratori
viral
infect
sot
patient
mild
selflimit
upper
respiratori
tract
infect
urti
requir
hospit
howev
compar
immunocompet
host
due
alter
cellular
humor
immun
infect
caus
protract
symptom
greater
risk
progress
lrti
prolong
period
viral
shed
increas
mortal
sot
lrti
associ
increas
risk
advers
complic
subsequ
develop
fungal
viral
bacteri
superinfect
although
complic
may
appear
context
type
transplant
pediatr
lung
heartlung
transplant
recipi
appear
greatest
risk
respiratori
viral
infect
sever
cours
complic
addit
direct
cytopath
tissueinvas
effect
rv
creat
inflammatori
environ
lead
local
system
microbi
determin
immun
modul
mdim
mdim
may
increas
alloimmun
autoimmun
respons
increas
suscept
opportunist
infect
associ
develop
acut
chronic
reject
greatest
risk
appear
data
lung
transplant
recipi
although
data
topic
literatur
conflict
transplant
overal
rhv
cov
common
etiolog
agent
caus
mostli
mild
urti
lrti
less
frequent
describ
contrast
flu
paramyxoviru
rsv
piv
hmpv
greater
associ
lrti
particularli
acut
chronic
reject
adult
lung
transplant
recipi
tabl
outcom
infect
associ
strongli
site
involv
net
state
immun
suppress
avail
use
antivir
agent
clinic
diagnosi
rv
difficult
sinc
sot
recipi
often
present
mild
atyp
symptom
sign
often
overlap
alway
specif
one
viral
agent
fever
absent
sot
pneumonia
sole
present
sign
addit
bacteri
fungal
coinfect
may
occur
distribut
rv
infect
throughout
year
suggest
season
pattern
rv
circul
sot
similar
circul
gener
popul
consequ
vigil
regard
circul
commun
rv
infect
requir
care
sot
recipi
rapid
reliabl
laboratori
diagnosi
requir
sot
respiratori
syndrom
significantli
impact
patient
care
manag
ideal
method
sampl
also
come
question
yield
viral
specimen
may
differ
depend
specimen
sourc
sot
suspect
rv
infect
nasopharyng
sampl
test
pcr
includ
nasopharyng
swab
np
wash
aspir
common
respiratori
specimen
collect
upper
respiratori
tract
np
prefer
sinc
practic
widespread
use
compar
sensit
nasopharyng
aspir
bronchoalveolar
lavag
bal
detect
major
rv
np
collect
dilig
train
staff
use
standard
procedur
center
diseas
control
prevent
cdc
http
wwwcdcgovurdodownloadsspeccollectionguidelinespdf
http
wwwyoutubecomwatch
vdvjnwefmhj
upper
tract
sampl
fail
document
rv
caus
respiratori
ill
clinic
radiolog
evid
lower
tract
involv
exist
bal
perform
rv
test
array
diagnost
tool
rv
immunocompromis
patient
greatli
increas
last
year
diagnosi
perform
use
realtim
pcr
rtpcr
techniqu
antigen
detect
serolog
tabl
sensit
contemporari
molecular
diagnost
techniqu
substanti
improv
allow
rapid
simultan
detect
wide
varieti
convent
emerg
rv
respiratori
sampl
present
realtim
multiplex
nucleic
acid
amplif
test
multiplex
nat
base
rtpcr
technolog
prefer
diagnost
tool
studi
rv
immunocompromis
patient
incorpor
mani
current
guidelin
laboratorydevelop
commerci
rtpcr
assay
current
avail
differ
specif
sensit
rang
best
sensit
seen
flu
lower
sensit
adv
piv
aim
overcom
technic
complex
pcrbase
test
fulli
autom
rtpcr
instrument
rapid
detect
rv
test
immunocompromis
patient
promis
result
turnaround
time
approxim
h
therefor
clinician
awar
perform
characterist
assay
perform
http
wwwcdcgovurdodownloadsspeccollectionguidelinespdf
note
regard
adv
neg
test
upper
lower
airway
may
exclud
infect
particularli
sot
dissemin
diseas
limit
involv
respiratori
tract
rtpcr
appli
respiratori
specimen
blood
quantit
viral
load
test
compart
depend
clinic
present
urin
cerebrospin
fluid
import
rememb
howev
despit
excel
sensit
poorli
collect
sampl
may
yield
falseneg
result
result
may
greatli
vari
depend
qualiti
swab
high
sensit
method
also
drawback
frequent
detect
virus
asymptomat
individu
prolong
detect
virus
patient
alreadi
clinic
recov
major
challeng
determin
associ
presenc
microbi
nucleic
acid
clinic
syndrom
individu
patient
quantif
viru
may
help
result
interpret
sinc
high
viral
load
associ
presenc
symptom
may
relat
sever
clinic
symptom
antigen
detect
techniqu
includ
immunofluoresc
immunoassay
ia
fast
high
specif
avail
specif
virus
sensit
less
molecular
method
techniqu
avail
viral
respiratori
infect
caus
rhv
cov
moder
complex
interpret
result
subject
number
commerci
ia
avail
rsv
flu
b
requir
littl
technic
expertis
howev
falseneg
falseposit
result
gener
low
preval
circul
viru
within
commun
decreas
posit
predict
valu
test
flu
rapid
ia
shown
high
specif
low
sensit
compar
assay
make
suboptim
sot
recipi
particularli
clinic
decisionmak
antivir
therapi
antivir
suscept
test
rv
primarili
focus
influenza
phenotyp
genotyp
assay
test
although
test
wide
avail
local
commerci
lab
antivir
resist
consider
concern
among
immunocompromis
patient
infect
influenza
viru
test
strongli
consid
sot
undergo
treatment
fail
appropri
clinic
respons
within
day
initi
antivir
therapi
relaps
cours
despit
ongo
therapi
absenc
avail
treatment
option
strong
evid
effect
particular
therapi
treatment
strategi
differ
wide
among
center
limit
understand
risk
factor
progress
sever
lrti
poor
outcom
indirect
inflammatori
effect
viral
infect
impact
opinion
appropri
intervent
respiratori
viral
infect
rv
infect
particularli
caus
influenza
viru
risk
factor
subsequ
bacteri
fungal
superinfect
case
lrti
secondari
infect
must
rule
appropri
treat
initi
oral
nebul
antifung
prophylaxi
prevent
invas
fungal
infect
evalu
highrisk
patient
manag
transplant
patient
gener
focus
reduct
immunosuppress
feasibl
speed
resolut
viral
infect
treatment
option
rv
limit
tabl
resist
pattern
may
chang
affect
recommend
antivir
strategi
consequ
clinician
consult
nation
health
author
regularli
updat
recommend
especi
influenza
opinion
treatment
effort
alway
perform
sot
lrti
lung
transplant
heartlung
transplant
recipi
urti
lrti
due
increas
morbid
mortal
reconstitut
immun
system
appear
import
overcom
rv
infect
clearli
current
avail
treatment
option
clinic
dilemma
numer
report
literatur
cite
use
intraven
immunoglobulin
ivig
part
therapi
viral
infect
immunocompromis
patient
hypogammaglobulinemia
associ
increas
risk
opportunist
infect
sot
communityacquir
rvi
howev
expert
recommend
consid
addit
ivig
sever
rv
infect
sot
use
monoclon
antibodi
limit
treatment
rsv
immunotherapi
includ
transfer
rvspecif
lymphocyt
healthi
donor
investig
report
safe
effect
perform
earli
cours
infect
hmpv
adenoviru
rsv
piv
time
virusassoci
immun
modul
may
sometim
deleteri
rv
due
local
inflammatori
respons
adjunct
therapi
corticosteroid
purpos
sot
influenza
rsv
lung
transplant
recipi
rv
lrti
risk
acut
chronic
reject
treatment
option
rv
limit
maxim
prevent
measur
viral
infect
sot
mandatori
rv
potenti
commun
nosocomi
pathogen
spread
staff
visitor
mild
upper
respiratori
ill
overal
awar
among
sot
healthcar
personnel
famili
member
caregiv
potenti
deleteri
outcom
rv
infect
sot
import
earli
detect
infect
may
signific
impact
incid
rv
infect
risk
transmiss
strict
adher
hand
hygien
contact
precaut
respiratori
droplet
isol
requir
reduc
rv
nosocomi
spread
outbreak
hospit
tabl
http
wwwcdcgovinfectioncontrolguidelinesisol
appropri
length
isol
patient
laboratori
proven
rv
debat
prolong
shed
common
find
sot
patient
viral
load
threshold
infect
unknown
infect
control
measur
maintain
patient
discharg
home
pcr
neg
stringent
hygien
precaut
also
appli
commun
set
sot
recipi
avoid
close
contact
individu
respiratori
tract
infect
influenza
viru
current
carv
prevent
vaccin
mainstay
treatment
influenza
b
neuraminidas
inhibitor
nai
mainli
oseltamivir
tabl
doubl
treatment
dose
oseltamivir
hospit
patient
influenza
seem
increas
virolog
efficaci
except
perhap
influenza
b
infect
case
oral
absorpt
concern
evid
emerg
oseltamivir
resist
zanamivir
use
less
frequent
oral
oseltamivir
like
due
inhal
deliveri
rout
although
shown
better
activ
influenza
b
crossresist
oseltamivir
regard
intraven
formul
avail
intraven
zanamivir
peramivir
consid
sot
recipi
sever
ill
despit
oral
oseltamivir
case
concern
oral
absorpt
although
experi
drug
sot
recipi
lack
parenter
zanamivir
current
avail
europ
singl
dose
intraven
peramivir
approv
unit
state
treatment
uncompl
influenza
infect
howev
peramivir
use
sot
like
would
requir
repeat
dose
switch
oral
oseltamivir
complet
therapi
nai
resist
current
uncommon
isol
especi
influenza
influenza
b
virus
remain
area
grow
concern
case
highlevel
oseltamivir
resist
virus
strain
substitut
peramivir
usual
preserv
reduc
suscept
zanamivir
usual
activ
anoth
common
resist
mutat
confer
resist
oseltamivir
peramivir
zanamivir
therefor
peramivir
use
patient
oseltamivir
resist
unless
isol
proven
suscept
tabl
inhal
sialidas
potenti
inhibit
influenza
parainfluenza
infect
shown
promis
vitro
result
activ
oseltamivirresist
influenza
strain
fail
show
superior
compar
placebo
previou
studi
healthi
subject
influenza
infect
treatment
initi
soon
possibl
sinc
antivir
therapi
like
provid
benefit
initi
within
first
h
ill
sot
reduc
rate
influenzaassoci
complic
admiss
icu
use
invas
ventil
death
howev
benefit
demonstr
even
delay
treatment
expert
endors
influenzaspecif
antivir
treatment
point
ill
treatment
delay
await
diagnost
test
result
rapid
antigen
ia
test
neg
clinic
symptom
suggest
infect
due
poor
sensit
rapid
antigen
test
tabl
gener
durat
antivir
therapi
least
day
sot
patient
although
data
suggest
longer
durat
day
may
requir
particularli
critic
ill
patient
pneumonia
persist
viral
shed
asid
advanc
support
care
specif
adjunct
therapi
routin
recommend
corticosteroid
shown
decreas
need
mechan
ventil
progress
lrti
cost
prolong
viral
shed
risk
invas
fungal
coinfect
corticosteroid
routin
recommend
use
indic
anoth
reason
concurr
acut
reject
main
prevent
strategi
influenza
sot
recipi
remain
administr
yearli
inactiv
influenza
vaccin
transplant
recipi
candid
well
famili
member
close
contact
healthcar
worker
receiv
influenza
vaccin
provid
herd
immun
tabl
influenza
vaccin
avail
inactiv
intramuscular
intraderm
administr
liveattenu
intranas
formul
liveattenu
vaccin
recommend
immunocompromis
recipi
close
contact
due
potenti
risk
dissemin
vaccin
current
guidelin
recommend
standard
inject
inactiv
influenza
sot
start
month
posttransplant
option
administr
earli
month
posttransplant
outbreak
set
influenza
vaccin
administ
earlier
month
posttransplant
like
less
effect
consider
may
given
administ
second
dose
vaccin
later
influenza
season
associ
vaccin
develop
de
novo
antibodi
graft
reject
unproven
higherdos
vaccin
pediatr
sot
booster
strategi
week
standard
influenza
vaccin
adult
sot
shown
induc
increas
antibodi
respons
compar
standard
singl
dose
whether
protect
increas
use
higherdos
vaccin
adjuv
booster
dose
quadrival
versu
trival
vaccin
constitut
area
activ
research
clinic
failur
influenza
vaccin
sot
recipi
extens
studi
studi
clearli
suggest
reduc
immun
respons
sot
seroconvers
rate
vari
although
also
depend
match
vaccin
circul
strain
vaccin
shown
attenu
advers
outcom
among
sot
recipi
lower
incid
pneumonia
shorter
length
hospit
stay
beyond
influenza
vaccin
preexposur
postexposur
chemoprophylaxi
either
oseltamivir
zanamivir
approv
tabl
may
consid
caution
use
prescrib
oseltamivir
prophylaxi
patient
expos
index
case
prophylaxi
associ
emerg
resist
mutant
therefor
monitor
empir
therapi
gener
recommend
case
use
ribavirin
rbv
treatment
rsv
infect
controversi
immunocompromis
patient
mainli
hematopoiet
stem
cell
transplant
recipi
rbv
shown
decreas
progress
lrti
given
patient
urti
among
sot
greatest
experi
rbv
lung
transplant
recipi
base
publish
report
well
selfreport
treatment
strategi
survey
sot
center
lung
heartlung
recipi
often
receiv
rbv
rsvrelat
urti
lrti
due
lack
clear
evid
efficaci
wide
variat
manag
rsv
exist
includ
variabl
often
depend
avail
inhal
intraven
oral
rbv
formul
intraven
inhal
rbv
avail
european
countri
oral
ribavirin
appear
effect
welltoler
altern
intraven
inhal
ribavirin
provid
potenti
cost
save
reduc
length
hospit
stay
tabl
small
interf
rna
target
rsv
nucleocapsid
messeng
rna
shown
earli
promis
potenti
prevent
chronic
reject
lung
transplant
recipi
rsv
agent
longer
develop
clinic
addit
number
small
molecul
therapi
variou
stage
develop
includ
earli
clinic
trial
immunomodul
also
investig
expert
recommend
consid
addit
antibodi
prepar
palivizumab
ivig
without
corticosteroid
sever
rsv
infect
sot
although
data
limit
support
recommend
systemat
review
report
form
rbv
alon
combin
immunomodulatori
agent
effect
prevent
progress
urti
lrti
trend
toward
better
outcom
inhal
rbv
plu
immunomodulatori
monoclon
palivizumab
polyclon
antibodi
prepar
ivig
tabl
addit
gener
prevent
measur
fdaapprov
agent
prevent
sever
rsv
infect
highrisk
patient
age
year
palivizumab
survey
data
suggest
antibodybas
prophylaxi
use
among
pediatr
transplant
center
young
candid
recipi
howev
guidelin
regard
use
agent
older
children
adult
exist
high
combin
lack
clear
evid
efficaci
sot
recipi
preclud
widescal
use
tabl
current
approv
antivir
treatment
parainfluenza
diseas
treatment
support
includ
reduct
immunosuppress
oral
aerosol
intraven
rbv
andor
ivig
corticosteroid
use
offlabel
piv
variabl
result
impact
mortal
use
treat
piv
infect
immunocompromis
patient
shown
encourag
result
includ
reduct
piv
quantit
viral
load
overal
outcom
clinic
trial
result
pend
outbreak
caus
piv
report
previous
patient
known
suspect
piv
isol
standard
contact
precaut
approv
vaccin
prophylact
antivir
agent
approv
drug
treatment
hmpv
respiratori
infect
support
therapi
main
treatment
although
rbv
alon
ivig
could
consid
manag
lrti
sever
case
hmpv
sot
approv
vaccin
prophylact
antivir
agent
specif
treatment
approv
rhinoviru
infect
approv
vaccin
prophylact
antivir
agent
antivir
licens
treatment
hcov
infect
therapi
consist
support
care
rbv
use
treatment
lrti
caus
coronaviru
outbreak
sar
use
rbv
combin
merscov
report
howev
combin
report
sot
specif
data
recommend
rbv
treatment
cov
infect
sot
recipi
approv
vaccin
prophylact
antivir
agent
treatment
support
includ
reduct
immunosuppress
optim
time
therapeut
intervent
cours
ill
unclear
exist
data
suggest
cidofovir
brincidofovir
oral
bioavail
lipid
conjug
cidofovir
may
provid
highest
likelihood
antivir
efficaci
brincidofovir
appear
increas
vitro
vivo
efficaci
adv
treatment
seriou
infect
less
renal
bone
marrow
toxic
cidofovir
tabl
rbv
appear
signific
antiadv
activ
human
gener
recommend
treat
seriou
adv
infect
use
ivig
remain
controversi
appear
clear
benefit
time
adopt
tcell
transfer
gener
limit
center
predominantli
hematopoiet
stem
cell
transplant
report
safe
effect
perform
earli
cours
infect
approv
vaccin
prophylact
antivir
agent
longitudin
prospect
surveil
use
molecular
diagnost
need
understand
true
epidemiolog
clinic
spectrum
respiratori
viral
diseas
sot
particularli
nonlung
popul
optim
time
durat
treatment
indic
rv
dilemma
need
clarifi
clinic
practic
efficaci
adjuv
immunogen
therapi
remain
controversi
maxim
prevent
infect
control
measur
rv
sot
essenti
tabl
